Cartiva completed enrollment and treatment of all 50 patients in a multi-center study evaluating the Synthetic Cartilage Implant (SCI) for first carpometacarpal joint osteoarthritis (OA) at the base of the thumb. The study was conducted at nine sites in Canada and the U.K.
In 3Q16, Cartiva received Premarket Approval from FDA for use of SCI to treat OA at the base of the great toe. Cartiva is now focused on patient follow-up and data analysis for the current study; next month, the company will discuss interim 6-month study results with FDA for the thumb indication.
SCI is a biocompatible polymer device designed to mimic natural cartilage and minimize bone resection while preserving the trapezium. This may yield a faster recovery than trapeziectomy.
Cartiva completed enrollment and treatment of all 50 patients in a multi-center study evaluating the Synthetic Cartilage Implant (SCI) for first carpometacarpal joint osteoarthritis (OA) at the base of the thumb. The study was conducted at nine sites in Canada and the U.K.
In 3Q16, Cartiva received Premarket Approval from FDA for use of SCI to...
Cartiva completed enrollment and treatment of all 50 patients in a multi-center study evaluating the Synthetic Cartilage Implant (SCI) for first carpometacarpal joint osteoarthritis (OA) at the base of the thumb. The study was conducted at nine sites in Canada and the U.K.
In 3Q16, Cartiva received Premarket Approval from FDA for use of SCI to treat OA at the base of the great toe. Cartiva is now focused on patient follow-up and data analysis for the current study; next month, the company will discuss interim 6-month study results with FDA for the thumb indication.
SCI is a biocompatible polymer device designed to mimic natural cartilage and minimize bone resection while preserving the trapezium. This may yield a faster recovery than trapeziectomy.
Copy to clipboard 
